This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer Medical Information

Menu

Close

HomeAbout DosingEfficacySafety and tolerabilityImportant safety information InteractionsFertility, Pregnancy and lactationUndesirable effectsGuidelinesResourcesProduct InformationEventsMaterialsVideos
Safety and tolerability

Undesirable effects

Very common ≥1/10

Gastrointestinal disorders
- Diarrhoea

Common ≥1/100 to <1/10

Infections and infestations
- Candida infection

Blood and lymphatic system disorders
- Thrombocytopenia anaemia

Psychiatric disorders
- Insomnia

Nervous system disorders
- Headache

Gastrointestinal disorders
- Abdominal pain, vomiting, constipation, nausea, dyspepsis

Skin and subcutaneous tissue disorders
- Rash, pruritus

General disorders and administration site conditions
- Pyrexia, injection site reaction

Investigations
- Alanine aminotransferase increased, aspartate aminotransferase increased, protein total decreased, blood albumin decreased, Coombs direct test positive, blood creatinine increased, blood alkaline phosphatase increased, blood urea increased, activated partial thromboplastin time prolonged

Uncommon ≥1/1,000 to <1/100

Blood and lymphatic system disorders
- Leukopenia

Metabolism and nutrition disorders
- Hypokalaemia

Nervous system disorders
- Seizures

Vascular disorders
- Hypotension, phlebitis, thrombophlebitis, flushing

Skin and subcutaneous tissue disorders
- Erythema multiforme, urticaria, rash maculo-papular

Musculoskeletal and connective tissue disorders
- Arthralgia, myalgia

General disorders and administration site conditions
- Chills

Investigations
- Blood glucose decreased, blood bilirubin increased, prothrombin time prolonged

Rare ≥1/10,000 to <1/1000

Infections and infestations
- Pseudomembranous colitis

Blood and lymphatic system disorders
- Agranulocytosis

Respiratory, thoracic and mediastinal disorders
- Epistaxis

Gastrointestinal disorders
- Stomatitis

Skin and subcutaneous tissue disorders
- Toxic epidermal necrolysis

Frequency not known (cannot be estimated from available data)

Blood and lymphatic system disorders
- Pancytopenia, neutropenia, haemolytic anaemia, thrombocytosis, eosinophilia

Immune system disorders
- Anaphylactoid shock, anaphylactic shock, anaphylactoid reaction, anaphylactic reaction, hypersensitivity kounis syndrome

Psychiatric disorders
- Delirium

Respiratory, thoracic and mediastinal disorders
- Eosinophilic pneumonia

Hepatobiliary disorders
- Hepatitis, jaundice

Skin and subcutaneous tissue disorders
- Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP), dermatitis exfoliative, dermatitis bullous, purpura

Renal and urinary disorders
- Renal failure, tubulointerstitial nephritis

Investigations
- Bleeding time prolonged, gamma-glutamyl transferase increased

Explore more safety and tolerability information Important safety information Learn more Loading Interactions Learn more LoadingReference:Pfizer Malaysia Tazocin® EF Prescribing Information. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17746. Accessed on 15 July 2024.
More safety and tolerability content
Guidelines Learn more Loading
Product Information View Product Information Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

PP-TAZ-MYS-0132-24JUL2024
You are now leaving the PfizerPro Malaysia website
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023